- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04691661
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is will be conducting to determine if Radotinib is safe and can be tolerated by patients with Parkinson's disease (PD) and to learn if Radotinib can be potential therapeutic agents for the treatment of PD.
Radotinib has been approved by Ministry of Food & Drug Safety of Korea to treat Chronic Myeloid Leukemia (CML) but it has not been approved for PD.
In nonclinical efficacy study, therapeutic effect of Radotinib HCl, c-Abl inhibitor, which exhibits improved pharmacokinetic properties and BBB penetration compared to nilotinib and other c-Abl inhibitors, was tested in a preclinical α-synuclein preformed fibrils (PFF) model of sporadic PD. As a result, the treatment of Radotinib HCl protects the α-synuclein PFFs-induced neuronal toxicity, reduces the PFFs-induced LB/LN-like pathology, and inhibits the PFFs-induced c-Abl activation in neurons. In vivo studies demonstrate that administration of Radotinib HCl prevents dopamine neuron loss and behavioral deficits following α-synuclein PFFs-induced toxicity. Taken together, these findings indicate that Radotinib HCl has beneficial neuroprotective effects in PD and provides strong evidence that selective and brain permeable c-Abl inhibitors can be potential therapeutic agents for the treatment of PD.
These data are very compelling to evaluate the effects of Radotinib in a phase II, randomized, double-blind, placebo-controlled trial in patients with PD.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: IL-YANG CR
- Phone Number: +82.70.7165.7316
- Email: nykim@ilyanga.co.kr
Study Locations
-
-
-
Lille, France
- Not yet recruiting
- CHRU de Lille - Hôpital Roger Salengro
-
Contact:
- Luc DEFEBVRE
-
Limoges, France
- Active, not recruiting
- CHU Limoges
-
Lyon, France
- Active, not recruiting
- CHU de Lyon HCL
-
Nantes, France
- Recruiting
- Hôpital Nantes-Hotel Dieu
-
Contact:
- Damier Philippe
-
Paris, France
- Active, not recruiting
- Hôpital Pitié-Salpêtrière
-
Poitiers, France
- Active, not recruiting
- CHU La Miletrie
-
Rouen, France
- Recruiting
- CHU de Rouen
-
Contact:
- David MALTETE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and Female from 40 to 80 years old;
- Diagnosed with "Clinically Probable Parkinson's Disease" according to the MDS clinical diagnostic criteria, with documented onset of symptoms per treating physician's records within three years of the screening visit;
- Positive DAT-scan (e.g. a striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT, characterized by crescent-shaped areas of asymmetrical aspect, or of symmetrical aspect but of uneven intensity, between the right and the left brain hemisphere) confirmed by local reading;
- Hoehn & Yahr stage ≤ 2.5;
- Without previous symptomatic treatment for PD disease and with current clinical state not requiring started dopaminergic therapy within 6 months from Baseline;
- Absence of a parkinsonian syndrome and other neurovascular comorbidities, confirmed by MRI
- Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or postmenopausal (at least 12 months since last menses) or using highly effective method of birth control defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intra uterine devices (IUDs), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, condom, until at least one month after the last drug intake associated to a negative pregnancy test at screening;
- Covered by Health Insurance System;
- Able to understand and to sign the informed consent prior to screening;
- Blood Pressure (BP) and Heart Rate (HR) considered NCS by Investigator;
- Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by Investigator;
- Laboratory parameters within the normal range of the laboratory. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator.
Exclusion Criteria:
- Atypical Parkinsonism or drug-induced Parkinsonism;
- Current, or within 60 days of screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD.
- Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine, rasagiline) for 30 or more days any time in the past;
- Cognitive impairment (MMSE ≤ 24);
- Active psychiatric disorder (mood disorders, hallucinations or delirium with strong functional impact and not controlled by medication or which happened during the last 3 months before inclusion);
- Severe or uncontrolled chronic disease;
- Significant medical history of congenital or acquired bleeding disorders;
- Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel;
Any below impaired cardiac function:
- LVEF <45% or < lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram (if the subject has already carried out this examination during the last month before inclusion, he/she will be exempted from retaking this examination, but he/she will have to present the echocardiogram as well as the cardiologist's report. If not, this exam should be performed during the screening period)
- Subjects who cannot have QT intervals measured according to ECG
- Complete left bundle branch block
- Subjects with cardiac pacemakers
- Subjects with congenital long QT syndrome or the family history of known long QT syndrome
- History of, or presence of symptomatic ventricular or atrial tachyarrhythmias
- Clinically significant resting bradycardia (< 50 bpm).
- Mean QTcF >450msec following three consecutive ECG tests at baseline: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF >450msec and the electrolyte is not within the normal range
- Medical history of clinically confirmed myocardial infarction
- Medical history of unstable angina (within last 12 months)
- Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)
- Participation in other investigational drug trials within 30 days prior to Screening;
- Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations;
- Subjects currently receiving treatment with a strong CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbitol, St. John's Wort) or therapeutic Cumarin derivatives (e.g. warfarin, acenocoumarol, phenprocoumon) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs
- Subjects who are currently receiving treatment with a medication that has the potential to extend QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs (list of medications that have the potential to prolong QT interval is provided in the Appendix II) If subjects need to start such drug treatments during the study, this will be discussed with the sponsor, IL-YANG PHARM. Co., Ltd.
- Subjects who are currently receiving treatment with P-gp inducers (e.g. (Ritonavir, Saquinavir, Nelfinavir, Indinavir, Amprenavir, Tipranavir…), Apalutamide, Estrone, Estriol, Trazodone, Vincristine, Tamoxifen, Doxorubicin, Carbamazepine, Oxcarbazepine, Fosphenytoin, Lorlatinib, Phenobarbital, Phenytoin, Propofol, beclomethasone, Dexamethasone, Prednisone, Hydrocortisone, Diclofenac, Rifampicin, Reserpine, Nifedipine, Digoxine, Amiodarone, Spironolactone, Levothyroxine, Tacrolimus, Sirolimus, St. John's Wort (herbal ingredient)) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs;
- Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product;
- Medical history of acute or chronic pancreatitis within the past one year;
- Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease;
- Subjects known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C subjects can be enrolled;
- Men subjects who are unwilling to use and appropriate method of contraception during the study;
- Subjects who have hypersensitivity to active ingredient or any of the excipients of this investigational product;
- Any medical condition that might interfere with the protocol except those defined in Section 5.3 of the study protocol;
- Subject unable to attend scheduled visits or to comply to the protocol;
- Subject under legal guardianship or judicial protection;
- Subject in the exclusion period of another protocol;
- No possibility of contact in case of emergency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo: Dose escalation
Forty (40) subject will be recruited and randomized into 4 dosing groups.
In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
|
Placebo
|
Experimental: Radotinib HCl: Dose escalation
Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level. The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC). |
Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of safety parameters: Adverse Events
Time Frame: 12 months after dose administration
|
Incidence and severity of treatment emergent AEs
|
12 months after dose administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics assessments of Radotinib HCl: Cmax
Time Frame: 14 days after dose administration
|
The maximum (peak) observed drug concentration after dose administration
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: Tmax
Time Frame: 14 days after dose administration
|
The time to reach maximum (peak) drug concentration after dose administration
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: Ctrough
Time Frame: 14 days after dose administration
|
Trough plasma concentration (measured concentration at the end of a dosing interval at steady state)
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: AUCt
Time Frame: 14 days after dose administration
|
Area under the plasma concentration-time curve from time zero to time t
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: AUCinf
Time Frame: 14 days after dose administration
|
Area under plasma concentration-time curve from time 0 to infinity
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: AUC0-12h
Time Frame: 14 days after dose administration
|
Area under the plasma concentration-time curve over the last 24-h dosing interval
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: t1/2
Time Frame: 14 days after dose administration
|
Elimination half-life of Radotinib after dose administration
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: Vd/F
Time Frame: 14 days after dose administration
|
Apparent volume of distribution after non-intravenous administration
|
14 days after dose administration
|
Pharmacokinetics assessments of Radotinib HCl: CL/F
Time Frame: 14 days after dose administration
|
Apparent total clearance of the drug from plasma after oral administration
|
14 days after dose administration
|
Change from Baseline in the sum of MDS-UPDRS Parts I, II and III
Time Frame: 6 months
|
The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living, Part III (motor examination) and Part IV (motor complications). Only Parts I, II and III will be completed in this study. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse tremor/motor function. Larger differences will infer greater effect size for the intervention. Score drops over time imply improvement in tremor/motor function. |
6 months
|
Time from baseline to initiation of dopamine-replacement medication.
Time Frame: 6 months
|
Time from baseline to initiation of dopamine replacement therapy following randomization
|
6 months
|
Change in health related quality of life as measured by a quality of life questionnaire (PDQ-39)
Time Frame: 12 months
|
The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson's Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication.
The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).
|
12 months
|
Subject's clinical global impression of change.
Time Frame: 12 months
|
The CGI Scale of Global Clinical Impressions (see Appendix VI) allows an overall assessment of the subject's condition.
The CGI addresses the majority of mental disorders.
In its first item, rated from 1 to 7 (the rating 1 corresponding to the normal state), it allows a good overall measurement of the subject's condition.
The 2nd item proposes to the Investigator to evaluate the overall improvement of the subject compared to his/her condition at the admission to the research.
As before, this item has 7 quantified degrees (from 1 = "very strongly improved" to 7 = "very strongly aggravated").
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain DaT SPECT to measure dopamine neurons and nerve terminals
Time Frame: 12 months
|
DaTscan is a specific type of single-photon emission computed tomography (SPECT) imaging technique that helps visualize dopamine transporter in the brain
|
12 months
|
Concentration of α-synuclein in CSF
Time Frame: 6 months
|
Quantification of α-synuclein concentration in CSF
|
6 months
|
Concentration of Tau and phospho-Tau (p-181) in CSF
Time Frame: 6 months
|
Quantification of Tau and phospho-Tau (p-181) concentration in CSF
|
6 months
|
Concentration of β-amyloid peptide 1-42 in CSF
Time Frame: 6 months
|
Quantification of β-amyloid peptide 1-42 concentration in CSF
|
6 months
|
Concentration of NF-L in the serum
Time Frame: 6 months
|
Quantification of NF-L concentration in CSF
|
6 months
|
Concentration of Radotinib HCl in the CSF and plasma
Time Frame: 6 months
|
Quantification of Radotinib HCl concentration in CSF
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philippe DAMIER, Pr., CHU Nantes - Hôpital Nord Guillaume et René Laennec
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RT51EP1902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States